NEW: Premarket Now Starts at 4AM!

We’re excited to announce the extension of premarket and aftermarket hours! Our members now have access to quotes daily from 4:00 AM to 8:00 PM ET — offering greater flexibility and deeper insights into market trends beyond regular trading hours.

Upgrade to FINVIZ*Elite to access premarket quotes »

SPRC

SciSparc Ltd

Apr 04 • 12:01PM ET

0.2746

Dollar change -0.0258
Percentage change -8.59	%

Healthcare • Biotechnology • Israel • NASD

Peers: SYBX HCWB MRKR MTVA AFMD GOVX BCTX QNTM BFRG CMND

Scroll to Statements

Index	-	P/E	-	EPS (ttm)	-4.87	Insider Own	0.00%	Shs Outstand	10.83M	Perf Week	-10.84%
Market Cap	2.97M	Forward P/E	-	EPS next Y	-	Insider Trans	-	Shs Float	10.83M	Perf Month	-13.38%
Income	-5.68M	PEG	-	EPS next Q	-	Inst Own	1.72%	Short Float	9.53%	Perf Quarter	-30.06%
Sales	1.75M	P/S	1.70	EPS this Y	-	Inst Trans	0.66%	Short Ratio	0.17	Perf Half Y	21.08%
Book/sh	1.93	P/B	0.14	EPS next Y	-	ROA	-55.80%	Short Interest	1.03M	Perf Year	-85.08%
Cash/sh	0.24	P/C	1.13	EPS next 5Y	-	ROE	-103.20%	52W Range	0.20 - 2.10	Perf YTD	-23.72%
Dividend Est.	-	P/FCF	-	EPS past 5Y	-55.28%	ROI	-81.83%	52W High	-86.92%	Beta	0.78
Dividend TTM	-	Quick Ratio	1.63	Sales past 5Y	-	Gross Margin	-	52W Low	39.39%	ATR (14)	0.04
Dividend Ex-Date	-	Current Ratio	1.86	EPS Y/Y TTM	-350.84%	Oper. Margin	-395.94%	RSI (14)	34.34	Volatility	10.88% 12.56%
Employees	-	Debt/Eq	0.01	Sales Y/Y TTM	-47.36%	Profit Margin	-325.36%	Recom	1.00	Target Price	520.00
Option/Short	No / Yes	LT Debt/Eq	0.00	EPS Q/Q	-	Payout	-	Rel Volume	0.07	Prev Close	0.30
Sales Surprise	-	EPS Surprise	-	Sales Q/Q	-	Earnings	-	Avg Volume	6.05M	Price	0.27
SMA20	-16.91%	SMA50	-30.86%	SMA200	-32.19%	Trades		Volume	182,851	Change	-8.59%

Mar-10-25 07:45AM	SciSparc-Clearmind Collaboration Leads to Publication of Patent Application for Cocaine Addiction Psychedelic Combination Treatment in South Korea (GlobeNewswire) +25.16%
07:27AM	Clearmind Medicine Announces Publication of Patent for Cocaine Addiction Psychedelic Combination Treatment in South Korea (GlobeNewswire)
Mar-03-25 08:25AM	SciSparc Signs Definitive Agreement to Sell MitoCareX, Computational Drug Discovery Company Targeting Resistant Cancers (GlobeNewswire) -11.07%
Feb-27-25 08:45AM	SciSparc Extends $2 Million Loan to Support AutoMax's Growth Following AutoMax's Entry into Direct Import of JAC Electric Vehicles (GlobeNewswire)
Feb-26-25 09:29AM	N2OFF Signs Definitive Agreement to Acquire Next-Gen Computational Drug Discovery Company, Targeting Hard To Treat Cancers (GlobeNewswire)
07:17AM	Loading…
Feb-18-25 07:17AM	SciSparc Secures Favorable Settlement in Lawsuit It Filed, Receiving Cash Compensation and a Full Release from All Commitments, Royalties, and Allegations Asserted Against It on Claimed Core Technology (GlobeNewswire)
Feb-04-25 09:00AM	SciSparc-Clearmind Collaboration Leads to Publication of Patent for Binge Behaviour Combination Treatment in Mexico (GlobeNewswire) -8.89%
Jan-15-25 07:34AM	SciSparc Granted 180-Day Extension by Nasdaq to Regain Compliance with Minimum Bid Requirement (GlobeNewswire)
Jan-13-25 08:41AM	SciSparc: AutoMax Enters the Direct Import Market with a $13 Million First Shipment of JAC Electric Vehicles (GlobeNewswire)
Jan-08-25 07:30AM	SciSparc says MitoCareX expands research to pancreatic cancer (TipRanks) -20.92%
Jan-07-25 07:25AM	SciSparc: MitoCareX Bio Expands Research to Pancreatic Cancer Following Initial In-Vitro Positive Results (GlobeNewswire)
Jan-06-25 11:04AM	Why Is Psychedelic-SciSparc Stock Trading Higher On Monday? (Benzinga) +102.69%
08:15AM	Clearmind Medicine Announces the Publication of European Patent Application for Binge Behavior Psychedelic Combination Treatment (GlobeNewswire)
07:50AM	SciSparc-Clearmind Medicine Collaboration Announces the Publication of European Patent Application for Binge Behavior Psychedelic Combination Treatment (GlobeNewswire)
Jan-02-25 05:14AM	IMCA renews SciSparcs autism spectrum disorder therapy trial approval (Clinical Trials Arena) +9.06%
09:24AM	Loading…
Dec-31-24 09:24AM	SciSparc Announces Renewal of Approval by Israeli Medical Cannabis Agency for its Clinical Trial in Children with Autism Spectrum Disorder (GlobeNewswire) -22.70%
Dec-27-24 06:50AM	SciSparc: AutoMax announces $13M first delivery of JAC vehicles (TipRanks) -14.20%
Dec-26-24 09:21AM	SciSparc Shares Skyrocket With AutoMax's First JAC Motors Shipment (Benzinga) +126.04%
06:46AM	SciSparc: AutoMax Announces $13 Million First Delivery of JAC Vehicles Following Regulatory Approval for Direct Importation (GlobeNewswire)
Dec-16-24 07:40AM	SciSparc Provides Updates on Status of Spin-off of its Advanced Clinical Stage Pharmaceutical Portfolio to a Publicly Traded Company (GlobeNewswire) -15.56%
Nov-30-24 06:10AM	Jeffs Brands announces trademark registration approval for Wellution (TipRanks)
Oct-01-24 06:33AM	SciSparc receives FDA approval for trial for Tourette syndrome therapy (Clinical Trials Arena)
Sep-30-24 09:25AM	SciSparc Secures FDA Green Light to US Launch of its Pivotal Phase IIb Clinical Trial for Breakthrough Tourette Syndrome Treatment (GlobeNewswire)
Sep-26-24 09:05AM	SciSparc Signs Non-Binding Letter of Intent to Sell Stake in MitoCareX (GlobeNewswire)
Sep-23-24 08:17AM	SciSparc Receives FDA Approval to Initiate Phase IIb Clinical Trial for Tourette Syndrome Treatment (GlobeNewswire)
Sep-18-24 04:09PM	SciSparc Takes Major Step Forward with IND Application submitted to the FDA for Phase IIb Clinical Trial for Tourette Syndrome Treatment (GlobeNewswire)
Sep-16-24 04:06PM	SciSparc-Clearmind Medicine Collaboration Announces the Publication of an International Patent Application for Pioneering Ibogaine Combination Therapy (GlobeNewswire) -7.67%
04:06PM	Clearmind Medicine Announces the Notice of an International Patent Application for Pioneering Ibogaine Combination Therapy (GlobeNewswire)
Sep-11-24 07:40AM	SciSparc Advances $1.85 million Loan to AutoMax, Following AutoMax's Direct Import Agreement with Major Chinese Vehicle Manufacturer (GlobeNewswire)
Sep-06-24 07:55AM	SciSparc-Clearmind Medicine Collaboration Leads to Publication of International Patent Application for Innovative MDMA-Based Combination Treatment (GlobeNewswire)
07:55AM	Loading…
07:55AM	Clearmind Medicine Announces Publication of International Patent Application for Innovative MDMA-Based Combination Treatment (GlobeNewswire)
Aug-29-24 04:25PM	SciSparc-Clearmind Medicine Collaboration Leads to Publication of Application for Innovative Ketamine-Based Combination (GlobeNewswire) -13.04%
04:25PM	Clearmind Medicine Announces Publication of its Patent Application for Innovative Ketamine-Based Combination Treatment (GlobeNewswire)
Aug-28-24 08:55AM	SciSparc Grants Global Rights for Pain Therapy to Biotech Company in Agreement Worth up to $6 Million (GlobeNewswire)
Aug-26-24 04:52AM	SciSparc secures final approval in Israel to start Tourettes Syndrome trial (Clinical Trials Arena) +7.63%
04:32AM	SciSparc seeks FDA IND clearance for Phase IIb Tourette Syndrome treatment trial (Clinical Trials Arena)
Aug-23-24 04:09PM	SciSparc Submitted IND Application to the FDA for SCI-110 Phase IIb Clinical Trial for Patients with Tourette Syndrome (GlobeNewswire)
Aug-22-24 08:12AM	SciSparc: MitoCareX Appointed Professor Nir Peled, Seasoned Oncologist, to its Scientific Advisory Board (GlobeNewswire) -7.71%
Aug-19-24 04:11PM	SciSparc Announces Enrollment of the First Five Patients in the Clinical Trial of its Innovative SCI-210 Treatment (GlobeNewswire) +13.51%
06:33AM	SciSparc and Polyrizon sign global agreement for pain therapy (Pharmaceutical Technology)
Aug-16-24 04:30PM	SciSparc Finalizes Exclusive Global Out-Licensing Agreement for its Pain Therapy Valued at $3 million (GlobeNewswire) -7.27%
Aug-14-24 04:53PM	SciSparc Updates Regarding the Status of the AutoMax Merger (GlobeNewswire) -7.79% +23.87%
Aug-06-24 08:57AM	SciSparc's Collaboration with Clearmind Medicine Continues to Bear Fruit With New Scientific Article Showing MEAI Potential as a Novel Weight Loss Drug (GlobeNewswire) +8.47%
Jul-22-24 08:20AM	SciSparc: MitoCareX Confirms Potential Significant Role of its Drug Target in Non-Small Cell Lung Cancer (GlobeNewswire)
Jul-17-24 07:07AM	SciSparc Signs Non-Binding Letter of Intent for Exclusive Global Out-Licensing of Pain Treatment for Approximately $6 million (GlobeNewswire) -11.33%
Jul-16-24 11:55AM	SciSparc Ltd. Announces Receipt of Nasdaq Minimum Bid Price Notification (GlobeNewswire)
11:01AM	Mizuho Just Issued a Warning on Palantir (PLTR) Stock (InvestorPlace)
10:43AM	Why Is SciSparc (SPRC) Stock Up 25% Today? (InvestorPlace)
07:43AM	Today's Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Tuesday (InvestorPlace)
06:03AM	SciSparc Announces U.S. Patent Application for Treating Metabolic Syndrome and Weight Loss (GlobeNewswire)
06:03AM	Clearmind Medicine Announces Submission of US Patent Application for Treating Metabolic Syndrome and Weight-loss (GlobeNewswire)
Jul-08-24 08:30AM	SciSparc Signs Non-Binding Letter of Intent for Spin Off of Advanced Clinical Stage Pharmaceutical Portfolio to Publicly Traded Company (GlobeNewswire)
May-31-24 07:17AM	SciSparc Secures Strategic Advantage with Grant of European Patent (GlobeNewswire) -11.43%
Apr-11-24 08:15AM	SciSparc to Acquire AutoMax (GlobeNewswire) +6.25%
Mar-27-24 09:12AM	Clearmind Medicine Announces International Patent Application for Preventing and Treating Depression (GlobeNewswire) -6.45%
08:55AM	SciSparc- Clearmind Collaboration Evolves with New International Patent Application for Preventing and Treating Depression (GlobeNewswire)
Mar-21-24 08:58AM	SciSparc: MitoCareX Unveils Groundbreaking Discovery of Small Molecule Structure in Anti-Cancer Research (GlobeNewswire)
Mar-18-24 07:29AM	SciSparc Granted Another Patent, Strengthening its Core Technology in Canada (GlobeNewswire)
Mar-14-24 08:49AM	SciSparc Achieves Major Milestone with First Patient Dosed in Autism Spectrum Disorder Clinical Trial (GlobeNewswire) -7.50%
Mar-12-24 08:14AM	SciSparc: MitoCareX Reveals Promising Results with Discovery of Novel Anti-Cancer Small Molecule Structure (GlobeNewswire) -8.78%
Mar-08-24 07:11AM	SciSparc Announces Enrollment of First Patient for its Clinical Trial for Children with Autism Spectrum Disorder (GlobeNewswire) -6.11%
Mar-07-24 07:49AM	SciSparc Granted Patent for Core Technology in Multiple Jurisdictions in Europe (GlobeNewswire)
Mar-06-24 04:41PM	SciSparc Issued Canadian Patent for Opioids Reduction Use in Pain Management Technology (GlobeNewswire)
Feb-29-24 08:35AM	SciSparc Delivers Treatment for Autism Spectrum Disorder Clinical Trial Enabling Commencement of Dosing (GlobeNewswire)
Feb-27-24 09:30AM	EXCLUSIVE: Psychedelic-Focused Firm Clearmind Medicine Submits Three New International Patent Applications For MDMA, Ibogaine And Ketamine Compounds (Benzinga)
07:58AM	SciSparc-Clearmind Partnership Yields Three New International Patent Applications for MDMA, Ibogaine and Ketamine Compounds (GlobeNewswire)
07:58AM	Clearmind Medicine Submits Three Additional International Patent Applications for Innovative MDMA, Ibogaine and Ketamine Compounds (GlobeNewswire)
Feb-20-24 07:14AM	SciSparc and Clearmind Continue to Strengthen International Patent Portfolio with Next Generation Classic Psychedelic-Based Compounds (GlobeNewswire) +15.52%
07:14AM	Clearmind Medicine Submits Three International Patent Applications for Next Generation Classic Psychedelic-Based Compounds (GlobeNewswire)
Jan-29-24 07:18AM	SciSparc Announces Initiation of Patient Recruitment for its Clinical Trial with SCI-210 in Children with Autism Spectrum Disorder (GlobeNewswire) -15.43%
Jan-24-24 01:49PM	Why Is SciSparc (SPRC) Stock Up 50% Today? (InvestorPlace) +78.03%
07:42AM	SciSparc Ltd. Announces $20 Million Standby Equity Purchase Agreement (GlobeNewswire)
Jan-19-24 09:28AM	SciSparc Advances the Acquisition Process of a Leading Vehicle Importer Company in Israel with the provision of a Bridge Loan of $1.4 million (GlobeNewswire) -8.77%
Jan-04-24 07:18AM	SciSparc and Clearmind Medicine Reflect on Successful Collaboration in 2023 Aiming to Upgrade Wide Range of Psychedelic-Based Treatments (GlobeNewswire) -8.02%
07:18AM	Clearmind Medicine and SciSparc Reflect on Successful Collaboration in 2023 Aiming to Upgrade Wide Range of Psychedelic- Based Treatments (GlobeNewswire)
Dec-13-23 02:02PM	Why Is SciSparc (SPRC) Stock Up 25% Today? (InvestorPlace) +39.51%
08:18AM	SciSparc Announces Positive Results for MitoCareX Bio with its Drug Discovery Platform (GlobeNewswire)
Dec-07-23 09:05AM	SciSparc Provides Updates Regarding the Non-Binding Letter of Intent to Acquire Leading Vehicle Importer Company in Israel (GlobeNewswire) -6.12%
Dec-05-23 08:47AM	Clearmind Medicine Achieved Positive Results in Cocaine Addiction Treatment (GlobeNewswire)
Dec-01-23 08:14AM	Weight Loss Treatment: SciSparc's Obesity Drug Showed Positive Results in a Pre-Clinical Trial (GlobeNewswire)
Nov-28-23 08:55AM	SciSparc Adopts Limited Duration Shareholder Rights Plan (GlobeNewswire) -9.22%
08:25AM	SciSparc Announces Positive Results from its Weight Loss and Metabolic Disorder Program with its Proprietary Psychedelic-Based Treatment (GlobeNewswire)
Nov-27-23 08:41AM	SciSparc Announces Positive Results for MitoCareX Bio with its Drug Discovery Platform (GlobeNewswire)
Nov-24-23 08:55AM	New Hope for Children: SciSparc's patented CBD- Enhanced Solution for Autism Spectrum Disorder (GlobeNewswire) +35.22%
Nov-22-23 09:49AM	Why Is SciSparc (SPRC) Stock Up 20% Today? (InvestorPlace) +16.80%
07:42AM	SciSparc Signs Non-Binding Letter of Intent to Merge with Leading Vehicle Importer Company in Israel (GlobeNewswire)
Nov-15-23 10:55AM	Why Is SciSparc (SPRC) Stock Up 47% Today? (InvestorPlace) +48.17%
08:01AM	SciSparc Celebrates Major Breakthrough: Positive Results Show its Treatment has a Remarkable Impact on Alzheimer's Agitation (GlobeNewswire)
Nov-10-23 09:10AM	SciSparc Aims to Change Tourette Syndrome Treatments; Will Start a Phase IIb Trial with its Innovative Pharma-Grade THC-Based Medication (GlobeNewswire) -8.52%
Oct-31-23 11:08AM	Why Is SciSparc (SPRC) Stock Up 58% Today? (InvestorPlace) +64.81%
07:38AM	SciSparc Granted Patent from the Australian Patent Office for its Reduction of Opioids Use in Pain Management Technology (GlobeNewswire)
Oct-24-23 07:20AM	SciSparc Granted Patent for its Core Technology From the Australian Patent Office (GlobeNewswire) -13.72%
Oct-17-23 08:00AM	Why Is SciSparc (SPRC) Stock Up 105% Today? (InvestorPlace) +124.56%
Oct-16-23 09:45AM	Aegis Capital Corp. acted as Exclusive Placement Agent on a $5.0 Million Private Placement for SciSparc Ltd. (NASDAQ: SPRC) (ACCESSWIRE) -6.02%
08:17AM	SciSparc Ltd. Regains Compliance with Nasdaq Minimum Bid Price Notification (GlobeNewswire)
Oct-13-23 04:28PM	SciSparc Ltd. Announces Closing of $5.026 Million Private Placement (GlobeNewswire) -9.67%
Oct-11-23 09:15AM	SciSparc Ltd. Announces Pricing of $5.026 Million Private Placement (GlobeNewswire) -12.94%
Oct-03-23 07:33AM	SciSparc Granted European Patent for its Core Technology (GlobeNewswire) +38.59%
Sep-29-23 07:45AM	SciSparc Initiated Its Clinical Trial with SCI-210 in Pediatrics with Autism Spectrum Disorder (GlobeNewswire) -7.16%
Sep-27-23 07:58AM	SciSparc Announces Expected Implementation of 1-for-26 Reverse Share Split (GlobeNewswire) +32.86%

SciSparc Ltd. is a clinical stage pharmaceutical company, which focuses on creating and enhancing a portfolio of technologies and assets based on cannabinoid pharmaceuticals. The firm initiated two internal drug development programs based on repurposing an FDA approved synthetic cannabinoid (dronabinol): Joint Pharma developing THX-TS01 targeted to the treatment of TS and Brain Bright Pharma developing THX-ULD01 targeted to the high value and under-served market of MCIs. Its products include SCI-110, SCI-210, SCI-160, and CannAmide. The company was founded on August 23, 2004 and is headquartered in Tel Aviv, Israel.

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

SPRC

SciSparc Ltd

Upgrade your FINVIZ experience